首页> 外文期刊>Cell Stress and Chaperones >A cell-based screen for inhibitors of protein folding and degradation
【24h】

A cell-based screen for inhibitors of protein folding and degradation

机译:基于细胞的蛋白质折叠和降解抑制剂筛选

获取原文
获取原文并翻译 | 示例
           

摘要

Cancer cells are exposed to external and internal stresses by virtue of their unrestrained growth, hostile microenvironment, and increased mutation rate. These stresses impose a burden on protein folding and degradation pathways and suggest a route for therapeutic intervention in cancer. Proteasome and Hsp90 inhibitors are in clinical trials and a 20S proteasome inhibitor, Velcade, is an approved drug. Other points of intervention in the folding and degradation pathway may therefore be of interest. We describe a simple screen for inhibitors of protein synthesis, folding, and proteasomal degradation pathways in this paper. The molecular chaperone-dependent client v-Src was fused to firefly luciferase and expressed in HCT-116 colorectal tumor cells. Both luciferase and protein tyrosine kinase activity were preserved in cells expressing this fusion construct. Exposing these cells to the Hsp90 inhibitor geldanamycin caused a rapid reduction of luciferase and kinase activities and depletion of detergent-soluble v-Src::luciferase fusion protein. Hsp70 knockdown reduced v-Src::luciferase activity and, when combined with geldanamycin, caused a buildup of v-Src::luciferase and ubiquitinated proteins in a detergent-insoluble fraction. Proteasome inhibitors also decreased luciferase activity and caused a buildup of phosphotyrosine-containing proteins in a detergent-insoluble fraction. Protein synthesis inhibitors also reduced luciferase activity, but had less of an effect on phosphotyrosine levels. In contrast, certain histone deacetylase inhibitors increased luciferase and phosphotyrosine activity. A mass screen led to the identification of Hsp90 inhibitors, ubiquitin pathway inhibitors, inhibitors of Hsp70/Hsp40-mediated refolding, and protein synthesis inhibitors. The largest group of compounds identified in the screen increased luciferase activity, and some of these increase v-Src levels and activity. When used in conjunction with appropriate secondary assays, this screen is a powerful cell-based tool for studying compounds that affect protein synthesis, folding, and degradation.
机译:癌细胞因其不受限制的生长,不利的微环境和增加的突变率而受到外部和内部压力。这些压力增加了蛋白质折叠和降解途径的负担,并提出了对癌症进行治疗性干预的途径。蛋白酶体和Hsp90抑制剂正在临床试验中,而20S蛋白酶体抑制剂Velcade是批准的药物。因此,可能会对折叠和降解途径的其他干预点感兴趣。我们在本文中描述了蛋白质合成,折叠和蛋白酶体降解途径抑制剂的简单筛选。分子伴侣依赖客户v-Src与萤火虫荧光素酶融合,并在HCT-116大肠肿瘤细胞中表达。荧光素酶和蛋白酪氨酸激酶的活性都保留在表达该融合构建体的细胞中。将这些细胞暴露于Hsp90抑制剂格尔德霉素会导致荧光素酶和激酶活性快速降低,并消耗去污剂可溶性v-Src ::荧光素酶融合蛋白。 Hsp70敲低降低了v-Src ::荧光素酶的活性,当与格尔德霉素联合使用时,会在洗涤剂不溶的部分中引起v-Src ::荧光素酶和泛素化蛋白的积累。蛋白酶体抑制剂还降低了萤光素酶活性,并导致去污剂不溶级分中的含磷酸酪氨酸的蛋白质堆积。蛋白合成抑制剂也降低了萤光素酶的活性,但对磷酸酪氨酸水平的影响较小。相反,某些组蛋白脱乙酰基酶抑制剂增加了荧光素酶和磷酸酪氨酸的活性。大规模筛选导致鉴定Hsp90抑制剂,泛素途径抑制剂,Hsp70 / Hsp40介导的重折叠抑制剂和蛋白质合成抑制剂。筛选出的最大的一组化合物增加了萤光素酶的活性,其中一些增加了v-Src的水平和活性。当与适当的辅助测定结合使用时,此筛选器是一种功能强大的基于细胞的工具,用于研究影响蛋白质合成,折叠和降解的化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号